XTLB

XTL Biopharmaceuticals Ltd. Sponsored ADR · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website xtlbio.com
Employees(FY) -
ISIN US98386D3070

Performance

-5.41%

1W

-24.85%

1M

+179.04%

3M

+191.67%

6M

+142.55%

YTD

+98.64%

1Y

Profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Advanced Technical Analysis

Technical Analysis of XTLB 2024-05-03

Overview:

In analyzing the technical indicators for XTLB over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...

See more ...

Recent News & Updates

2024-04-28 19:33
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-03-19 22:15
XTL To Aquire The Social Proxy(Globenewswire)
2023-10-20 04:00
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel(Globenewswire)
2023-10-20 04:00
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency(Globenewswire)
2018-11-20 19:00
Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals Fundamental Analysis, Key Performance Indications(Yahoo Finance)
2018-10-31 22:09
XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update(Yahoo Finance)
2018-07-23 21:09
XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update(Yahoo Finance)
2018-05-29 05:37
XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update(Yahoo Finance)
2017-12-12 18:30
Wired News Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells(Yahoo Finance)
2017-12-05 23:08
XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements(Yahoo Finance)
2017-11-26 21:30
XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results(Yahoo Finance)
2017-10-22 23:23
XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements(Yahoo Finance)
2017-10-05 19:30
Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy(Yahoo Finance)
2017-10-04 19:50
Earnings Review and Free Research Report: DelMar Missed Earnings Expectations(Yahoo Finance)
2017-09-25 21:23
XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update(Yahoo Finance)
2017-09-11 21:00
XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome(Yahoo Finance)
2017-07-10 19:00
Featured Company News Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update(Yahoo Finance)
2017-06-14 21:00
XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update(Yahoo Finance)
2017-04-26 21:50
XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors(Yahoo Finance)
2017-04-04 21:10
XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome(Yahoo Finance)
2017-03-29 20:55
XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update(Yahoo Finance)
2017-03-21 21:22
XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors(Yahoo Finance)
2017-03-06 23:40
XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors(Yahoo Finance)
2017-02-28 19:30
XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement(Yahoo Finance)
2017-02-16 19:00
XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering(Yahoo Finance)
2017-02-12 20:08
XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome(Yahoo Finance)
2017-01-24 19:30
XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program(Yahoo Finance)
2017-01-04 19:30
XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome(Yahoo Finance)
2016-12-18 19:00
XTL Biopharmaceuticals to Present at Biotech Showcase(Yahoo Finance)
2016-12-05 19:30
XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update(Yahoo Finance)

Page 1 of 3

previousnext